Gliknik Inc. is a privately owned corporation committed to the discovery and development of novel biomolecules for autoimmune diseases and cancer.  The company capitalizes on its expertise in immunology and tumor immunology.  Gliknik’s lead compounds are novel T cell vaccines in clinical safety studies.  Gliknik also has created recombinant mimetics of intravenous immune globulin and recombinant mimetics of monoclonal antibodies.